Search

Your search keyword '"WICK, MICHAEL J."' showing total 241 results
Start Over Author "WICK, MICHAEL J."
241 results on '"WICK, MICHAEL J."'

3. Contributors

Author

Abernethy, Darrell R., primary, Agoram, Balaji, additional, Allen, John M., additional, Arnold, Mark E., additional, Atkinson, Arthur J., additional, Bateman, Thomas J., additional, Bergman, Kimberly, additional, Booth, Brian, additional, Boulton, David W., additional, Branch, Robert A., additional, Burckart, Gilbert J., additional, Buschmann, Mary, additional, Carmichael, Owen, additional, Chamberlain, Christine, additional, Chen, Ligong, additional, Daniels, Charles E., additional, Das, Promi, additional, Delfino, Jana G., additional, Van Den Anker, John N., additional, Dreisbach, Albert W., additional, Dyszel, Michael, additional, Earp, Justin C., additional, ElZarrad, M. Khair, additional, Enogieru, Osatohanmwen J., additional, Fletcher, Elimika Pfuma, additional, Foster, David M., additional, Frederiksen, Marilynn C., additional, Galetin, Aleksandra, additional, Garzone, Pamela D., additional, Giacomini, Kathleen M., additional, Gibbs, Megan A., additional, Gilbert, Jack A, additional, Gnjidic, Danijela, additional, Gombar, Charles T., additional, Grant, Denis M., additional, Grudzinskas, Charles, additional, Hamren, Bengt, additional, Holford, Nicholas H.G., additional, Huang, Shiew-Mei, additional, Iacona, Renee, additional, Isoherranen, Nina, additional, Jin, Denise, additional, Jones, Bridgette L., additional, Kearns, Gregory L., additional, Kortepeter, Cindy, additional, Kunkoski, Elizabeth, additional, Lau, S.W. Johnny, additional, Leptak, Christopher, additional, Lertora, Juan J.L., additional, Lesko, Lawrence J., additional, Liu, Jiang, additional, Liu, Qi, additional, Madabushi, Rajanikanth, additional, Miller, Raymond, additional, Mould, Diane R., additional, Muñoz, Monica, additional, Nolin, Thomas D., additional, Noveck, Robert Joseph, additional, Obach, R. Scott, additional, Pacanowski, Michael, additional, Paine, Mary F., additional, Peck, Carl C., additional, Ramamoorthy, Anuradha, additional, Rodrigues, A. David, additional, Rowland, Malcolm, additional, Sahajwalla, Chandrahas G., additional, Sahre, Martina Dagmar, additional, Schuck, Robert N., additional, Sharma, Khushboo, additional, Sissung, Tristan, additional, Stika, Catherine S., additional, Takimoto, Chris H., additional, Tomkinson, Helen, additional, Uetrecht, Jack, additional, Vicini, Paolo, additional, Vo, Karen D., additional, Wagner, John A., additional, Wang, Yaning, additional, Wang, Yow-Ming C., additional, Wells, Peter G., additional, Wick, Michael J., additional, Yee, Sook Wah, additional, Yin, Ophelia, additional, Zgheib, Nathalie K., additional, Zhang, Lei, additional, and Zhu, Hao, additional

Published
2022
Full Text
View/download PDF

4. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Author

Ferrarotto, Renata, Mitani, Yoshitsugu, Diao, Lixia, Guijarro, Irene, Wang, Jing, Zweidler-McKay, Patrick, Bell, Diana, William, William N, Glisson, Bonnie S, Wick, Michael J, Kapoun, Ann M, Patnaik, Amita, Eckhardt, Gail, Munster, Pamela, Faoro, Leonardo, Dupont, Jakob, Lee, J Jack, Futreal, Andrew, El-Naggar, Adel K, and Heymach, John V

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Pediatric Cancer, Digestive Diseases, Rare Diseases, Clinical Research, Pediatric, Dental/Oral and Craniofacial Disease, Genetics, Aetiology, 2.1 Biological and endogenous factors, Adult, Aged, Animals, Antineoplastic Agents, Biomarkers, Tumor, Bone Neoplasms, Carcinoma, Adenoid Cystic, DNA Mutational Analysis, Disease-Free Survival, Female, Genetic Predisposition to Disease, HEK293 Cells, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Liver Neoplasms, Male, Mice, Nude, Middle Aged, Molecular Targeted Therapy, Mutation, Phenotype, Predictive Value of Tests, Proportional Hazards Models, Receptor, Notch1, Retrospective Studies, Risk Factors, Salivary Gland Neoplasms, Time Factors, Transfection, Treatment Outcome, Xenograft Model Antitumor Assays, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Purpose Adenoid cystic carcinomas (ACCs) represent a heterogeneous group of chemotherapy refractory tumors, with a subset demonstrating an aggressive phenotype. We investigated the molecular underpinnings of this phenotype and assessed the Notch1 pathway as a potential therapeutic target. Methods We genotyped 102 ACCs that had available pathologic and clinical data. Notch1 activation was assessed by immunohistochemistry for Notch1 intracellular domain. Luciferase reporter assays were used to confirm Notch1 target gene expression in vitro. The Notch1 inhibitor brontictuzumab was tested in patient-derived xenografts from patients with ACC and in a patient with ACC who was enrolled in a phase I study. Results NOTCH1 mutations occurred predominantly (14 of 15 patients) in the negative regulatory region and Pro-Glu-Ser-Thr-rich domains, the same two hotspots seen in T-cell acute lymphoblastic leukemias, and led to pathway activation in vitro. NOTCH1-mutant tumors demonstrated significantly higher levels of Notch1 pathway activation than wild-type tumors on the basis of Notch1 intracellular domain staining ( P = .004). NOTCH1 mutations define a distinct aggressive ACC subgroup with a significantly higher likelihood of solid subtype ( P < .001), advanced-stage disease at diagnosis ( P = .02), higher rate of liver and bone metastasis ( P ≤ .02), shorter relapse-free survival (median, 13 v 34 months; P = .01), and shorter overall survival (median 30 v 122 months; P = .001) when compared with NOTCH1 wild-type tumors. Significant tumor growth inhibition with brontictuzumab was observed exclusively in the ACC patient-derived xenograft model that harbored a NOTCH1 activating mutation. Furthermore, an index patient with NOTCH1-mutant ACC had a partial response to brontictuzumab. Conclusion NOTCH1 mutations define a distinct disease phenotype characterized by solid histology, liver and bone metastasis, poor prognosis, and potential responsiveness to Notch1 inhibitors. Clinical studies targeting Notch1 in a genotype-defined ACC subgroup are warranted.

Published
2017

8. Abstract 3869: Short or long-term treatment with CDK4/6 inhibitors in patients with ER+ breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models

Author

Simonson, Alyssa, primary, Flores, Johnnie, additional, Lynch, Morgan, additional, Carpenter, Emily, additional, Hruzek, Justine, additional, Lund, Jim, additional, Herraiz, Natalia Baños, additional, Papadopoulos, Kyriakos, additional, Woude, Amy Vander, additional, Rodriguez, Gladys, additional, Chandana, Sreenivasa, additional, Gribbin, Thomas, additional, Lakhani, Nehal, additional, Hernandez, Tatiana, additional, de Miguel, Maria Jose, additional, Lang, Amy, additional, and Wick, Michael J., additional

Published
2023
Full Text
View/download PDF

10. Figures S1-S6 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer

Author

Puyang, Xiaoling, primary, Furman, Craig, primary, Zheng, Guo Zhu, primary, Wu, Zhenhua J., primary, Banka, Deepti, primary, Aithal, Kiran, primary, Agoulnik, Sergei, primary, Bolduc, David M., primary, Buonamici, Silvia, primary, Caleb, Benjamin, primary, Das, Subhasree, primary, Eckley, Sean, primary, Fekkes, Peter, primary, Hao, Ming-Hong, primary, Hart, Andrew, primary, Houtman, René, primary, Irwin, Sean, primary, Joshi, Jaya J., primary, Karr, Craig, primary, Kim, Amy, primary, Kumar, Namita, primary, Kumar, Pavan, primary, Kuznetsov, Galina, primary, Lai, Weidong G., primary, Larsen, Nicholas, primary, Mackenzie, Crystal, primary, Martin, Lesley-Ann, primary, Melchers, Diana, primary, Moriarty, Alyssa, primary, Nguyen, Tuong-Vi, primary, Norris, John, primary, O'Shea, Morgan, primary, Pancholi, Sunil, primary, Prajapati, Sudeep, primary, Rajagopalan, Sujatha, primary, Reynolds, Dominic J., primary, Rimkunas, Victoria, primary, Rioux, Nathalie, primary, Ribas, Ricardo, primary, Siu, Amy, primary, Sivakumar, Sasirekha, primary, Subramanian, Vanitha, primary, Thomas, Michael, primary, Vaillancourt, Frédéric H., primary, Wang, John, primary, Wardell, Suzanne, primary, Wick, Michael J., primary, Yao, Shihua, primary, Yu, Lihua, primary, Warmuth, Markus, primary, Smith, Peter G., primary, Zhu, Ping, primary, and Korpal, Manav, primary

Published
2023
Full Text
View/download PDF

11. Figure S6 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Author

Germann, Ursula A., primary, Furey, Brinley F., primary, Markland, William, primary, Hoover, Russell R., primary, Aronov, Alex M., primary, Roix, Jeffrey J., primary, Hale, Michael, primary, Boucher, Diane M., primary, Sorrell, David A., primary, Martinez-Botella, Gabriel, primary, Fitzgibbon, Matthew, primary, Shapiro, Paul, primary, Wick, Michael J., primary, Samadani, Ramin, primary, Meshaw, Kathryn, primary, Groover, Anna, primary, DeCrescenzo, Gary, primary, Namchuk, Mark, primary, Emery, Caroline M., primary, Saha, Saurabh, primary, and Welsch, Dean J., primary

Published
2023
Full Text
View/download PDF

12. Data from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer

Author

Furman, Craig, primary, Puyang, Xiaoling, primary, Zhang, Zhaojie, primary, Wu, Zhenhua J., primary, Banka, Deepti, primary, Aithal, Kiran B., primary, Albacker, Lee A., primary, Hao, Ming-Hong, primary, Irwin, Sean, primary, Kim, Amy, primary, Montesion, Meagan, primary, Moriarty, Alyssa D., primary, Murugesan, Karthikeyan, primary, Nguyen, Tuong-Vi, primary, Rimkunas, Victoria, primary, Sahmoud, Tarek, primary, Wick, Michael J., primary, Yao, Shihua, primary, Zhang, Xun, primary, Zeng, Hao, primary, Vaillancourt, Frédéric H., primary, Bolduc, David M., primary, Larsen, Nicholas, primary, Zheng, Guo Zhu, primary, Prajapati, Sudeep, primary, Zhu, Ping, primary, and Korpal, Manav, primary

Published
2023
Full Text
View/download PDF

13. Data from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer

Author

Puyang, Xiaoling, primary, Furman, Craig, primary, Zheng, Guo Zhu, primary, Wu, Zhenhua J., primary, Banka, Deepti, primary, Aithal, Kiran, primary, Agoulnik, Sergei, primary, Bolduc, David M., primary, Buonamici, Silvia, primary, Caleb, Benjamin, primary, Das, Subhasree, primary, Eckley, Sean, primary, Fekkes, Peter, primary, Hao, Ming-Hong, primary, Hart, Andrew, primary, Houtman, René, primary, Irwin, Sean, primary, Joshi, Jaya J., primary, Karr, Craig, primary, Kim, Amy, primary, Kumar, Namita, primary, Kumar, Pavan, primary, Kuznetsov, Galina, primary, Lai, Weidong G., primary, Larsen, Nicholas, primary, Mackenzie, Crystal, primary, Martin, Lesley-Ann, primary, Melchers, Diana, primary, Moriarty, Alyssa, primary, Nguyen, Tuong-Vi, primary, Norris, John, primary, O'Shea, Morgan, primary, Pancholi, Sunil, primary, Prajapati, Sudeep, primary, Rajagopalan, Sujatha, primary, Reynolds, Dominic J., primary, Rimkunas, Victoria, primary, Rioux, Nathalie, primary, Ribas, Ricardo, primary, Siu, Amy, primary, Sivakumar, Sasirekha, primary, Subramanian, Vanitha, primary, Thomas, Michael, primary, Vaillancourt, Frédéric H., primary, Wang, John, primary, Wardell, Suzanne, primary, Wick, Michael J., primary, Yao, Shihua, primary, Yu, Lihua, primary, Warmuth, Markus, primary, Smith, Peter G., primary, Zhu, Ping, primary, and Korpal, Manav, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer

Author

Furman, Craig, primary, Puyang, Xiaoling, primary, Zhang, Zhaojie, primary, Wu, Zhenhua J., primary, Banka, Deepti, primary, Aithal, Kiran B., primary, Albacker, Lee A., primary, Hao, Ming-Hong, primary, Irwin, Sean, primary, Kim, Amy, primary, Montesion, Meagan, primary, Moriarty, Alyssa D., primary, Murugesan, Karthikeyan, primary, Nguyen, Tuong-Vi, primary, Rimkunas, Victoria, primary, Sahmoud, Tarek, primary, Wick, Michael J., primary, Yao, Shihua, primary, Zhang, Xun, primary, Zeng, Hao, primary, Vaillancourt, Frédéric H., primary, Bolduc, David M., primary, Larsen, Nicholas, primary, Zheng, Guo Zhu, primary, Prajapati, Sudeep, primary, Zhu, Ping, primary, and Korpal, Manav, primary

Published
2023
Full Text
View/download PDF

15. Tables S3-S4 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer

Author

Puyang, Xiaoling, primary, Furman, Craig, primary, Zheng, Guo Zhu, primary, Wu, Zhenhua J., primary, Banka, Deepti, primary, Aithal, Kiran, primary, Agoulnik, Sergei, primary, Bolduc, David M., primary, Buonamici, Silvia, primary, Caleb, Benjamin, primary, Das, Subhasree, primary, Eckley, Sean, primary, Fekkes, Peter, primary, Hao, Ming-Hong, primary, Hart, Andrew, primary, Houtman, René, primary, Irwin, Sean, primary, Joshi, Jaya J., primary, Karr, Craig, primary, Kim, Amy, primary, Kumar, Namita, primary, Kumar, Pavan, primary, Kuznetsov, Galina, primary, Lai, Weidong G., primary, Larsen, Nicholas, primary, Mackenzie, Crystal, primary, Martin, Lesley-Ann, primary, Melchers, Diana, primary, Moriarty, Alyssa, primary, Nguyen, Tuong-Vi, primary, Norris, John, primary, O'Shea, Morgan, primary, Pancholi, Sunil, primary, Prajapati, Sudeep, primary, Rajagopalan, Sujatha, primary, Reynolds, Dominic J., primary, Rimkunas, Victoria, primary, Rioux, Nathalie, primary, Ribas, Ricardo, primary, Siu, Amy, primary, Sivakumar, Sasirekha, primary, Subramanian, Vanitha, primary, Thomas, Michael, primary, Vaillancourt, Frédéric H., primary, Wang, John, primary, Wardell, Suzanne, primary, Wick, Michael J., primary, Yao, Shihua, primary, Yu, Lihua, primary, Warmuth, Markus, primary, Smith, Peter G., primary, Zhu, Ping, primary, and Korpal, Manav, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer

Author

Furman, Craig, primary, Puyang, Xiaoling, primary, Zhang, Zhaojie, primary, Wu, Zhenhua J., primary, Banka, Deepti, primary, Aithal, Kiran B., primary, Albacker, Lee A., primary, Hao, Ming-Hong, primary, Irwin, Sean, primary, Kim, Amy, primary, Montesion, Meagan, primary, Moriarty, Alyssa D., primary, Murugesan, Karthikeyan, primary, Nguyen, Tuong-Vi, primary, Rimkunas, Victoria, primary, Sahmoud, Tarek, primary, Wick, Michael J., primary, Yao, Shihua, primary, Zhang, Xun, primary, Zeng, Hao, primary, Vaillancourt, Frédéric H., primary, Bolduc, David M., primary, Larsen, Nicholas, primary, Zheng, Guo Zhu, primary, Prajapati, Sudeep, primary, Zhu, Ping, primary, and Korpal, Manav, primary

Published
2023
Full Text
View/download PDF

17. Data from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Author

Germann, Ursula A., primary, Furey, Brinley F., primary, Markland, William, primary, Hoover, Russell R., primary, Aronov, Alex M., primary, Roix, Jeffrey J., primary, Hale, Michael, primary, Boucher, Diane M., primary, Sorrell, David A., primary, Martinez-Botella, Gabriel, primary, Fitzgibbon, Matthew, primary, Shapiro, Paul, primary, Wick, Michael J., primary, Samadani, Ramin, primary, Meshaw, Kathryn, primary, Groover, Anna, primary, DeCrescenzo, Gary, primary, Namchuk, Mark, primary, Emery, Caroline M., primary, Saha, Saurabh, primary, and Welsch, Dean J., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Methods from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer

Author

Puyang, Xiaoling, primary, Furman, Craig, primary, Zheng, Guo Zhu, primary, Wu, Zhenhua J., primary, Banka, Deepti, primary, Aithal, Kiran, primary, Agoulnik, Sergei, primary, Bolduc, David M., primary, Buonamici, Silvia, primary, Caleb, Benjamin, primary, Das, Subhasree, primary, Eckley, Sean, primary, Fekkes, Peter, primary, Hao, Ming-Hong, primary, Hart, Andrew, primary, Houtman, René, primary, Irwin, Sean, primary, Joshi, Jaya J., primary, Karr, Craig, primary, Kim, Amy, primary, Kumar, Namita, primary, Kumar, Pavan, primary, Kuznetsov, Galina, primary, Lai, Weidong G., primary, Larsen, Nicholas, primary, Mackenzie, Crystal, primary, Martin, Lesley-Ann, primary, Melchers, Diana, primary, Moriarty, Alyssa, primary, Nguyen, Tuong-Vi, primary, Norris, John, primary, O'Shea, Morgan, primary, Pancholi, Sunil, primary, Prajapati, Sudeep, primary, Rajagopalan, Sujatha, primary, Reynolds, Dominic J., primary, Rimkunas, Victoria, primary, Rioux, Nathalie, primary, Ribas, Ricardo, primary, Siu, Amy, primary, Sivakumar, Sasirekha, primary, Subramanian, Vanitha, primary, Thomas, Michael, primary, Vaillancourt, Frédéric H., primary, Wang, John, primary, Wardell, Suzanne, primary, Wick, Michael J., primary, Yao, Shihua, primary, Yu, Lihua, primary, Warmuth, Markus, primary, Smith, Peter G., primary, Zhu, Ping, primary, and Korpal, Manav, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Data: Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (ulixertinib) from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Author

Germann, Ursula A., primary, Furey, Brinley F., primary, Markland, William, primary, Hoover, Russell R., primary, Aronov, Alex M., primary, Roix, Jeffrey J., primary, Hale, Michael, primary, Boucher, Diane M., primary, Sorrell, David A., primary, Martinez-Botella, Gabriel, primary, Fitzgibbon, Matthew, primary, Shapiro, Paul, primary, Wick, Michael J., primary, Samadani, Ramin, primary, Meshaw, Kathryn, primary, Groover, Anna, primary, DeCrescenzo, Gary, primary, Namchuk, Mark, primary, Emery, Caroline M., primary, Saha, Saurabh, primary, and Welsch, Dean J., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure Legend from A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

Author

Calvo, Emiliano, primary, Soria, Jean-Charles, primary, Ma, Wen Wee, primary, Wang, Tao, primary, Bahleda, Rastilav, primary, Tolcher, Anthony W., primary, Gernhardt, Diana, primary, O'Connell, Joseph, primary, Millham, Robert, primary, Giri, Nagdeep, primary, Wick, Michael J., primary, Adjei, Alex A., primary, and Hidalgo, Manuel, primary

Published
2023
Full Text
View/download PDF

25. CLEAN supplementary material Daco+figi 1004 CCR Sesub v4.0 from A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

Author

Calvo, Emiliano, primary, Soria, Jean-Charles, primary, Ma, Wen Wee, primary, Wang, Tao, primary, Bahleda, Rastilav, primary, Tolcher, Anthony W., primary, Gernhardt, Diana, primary, O'Connell, Joseph, primary, Millham, Robert, primary, Giri, Nagdeep, primary, Wick, Michael J., primary, Adjei, Alex A., primary, and Hidalgo, Manuel, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures 1-6 + Supplementary Tables 1-2 from Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma

Author

Warner, Kristy A., primary, Nör, Felipe, primary, Acasigua, Gerson A., primary, Martins, Manoela D., primary, Zhang, Zhaocheng, primary, McLean, Scott A., primary, Spector, Matthew E., primary, Chepeha, Douglas B., primary, Helman, Joseph, primary, Wick, Michael J., primary, Moskaluk, Christopher A., primary, Castilho, Rogerio M., primary, Pearson, Alexander T., primary, Wang, Shaomeng, primary, and Nör, Jacques E., primary

Published
2023
Full Text
View/download PDF

27. CCR Translation for This Article from The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Author

Shimizu, Toshio, primary, Tolcher, Anthony W., primary, Papadopoulos, Kyriakos P., primary, Beeram, Muralidhar, primary, Rasco, Drew W., primary, Smith, Lon S., primary, Gunn, Shelly, primary, Smetzer, Leslie, primary, Mays, Theresa A., primary, Kaiser, Brianne, primary, Wick, Michael J., primary, Alvarez, Cathy, primary, Cavazos, Aracely, primary, Mangold, Gina L., primary, and Patnaik, Amita, primary

Published
2023
Full Text
View/download PDF

28. Using PDX animal models to identify and stratify adenoid cystic carcinoma patients presenting an enhanced response to HDAC inhibitors

Author

Guimarães, Leticia DA, Webber, Liana P, Gaio, Eduardo J, Junior, Decio SP, Gonçalves, Priscila, Wick, Michael J, Burr, Nicole S, Squarize, Cristiane H, and Castilho, Rogerio M

Subjects
Original Article
Abstract

Adenoid cystic carcinoma (ACC) patients face a highly infiltrative and metastatic disease characterized by poor survival rates and suboptimal response to available therapies. We have previously shown that sensitization of ACC tumors to chemotherapy using histone deacetylase inhibitors (HDACi) constitutes a promising therapeutic strategy to manage tumor growth. Here, we used patient-derived xenografts (PDX) from ACC tumors to evaluate the effects of in vivo administration of the HDAC inhibitor Entinostat combined with Cisplatin over tumor growth. RNA from PDX tumor samples receiving the proposed therapy were analyzed using NanoString technology to identify molecular signatures capable of predicting ACC response to the therapy. We also used an RNAseq dataset from 68 ACC patients to validate the molecular signature identified by the NanoString platform. We found that the administration of Entinostat combined with Cisplatin resulted in a potent tumor growth inhibition (TGI) ranging from 38% to 106% of the original tumor mass. Enhanced response to therapy is consistent with the reactivation of tumor suppressor genes, including SFRP1, and the downregulation of oncogenes like FGF8 and CCR7. Nanostring data from PDX tumors identified a genetic signature capable of predicting tumor response to therapy. We further stratified 68 ACC patients containing RNAseq data accordingly to the activity levels of the identified genetic signature. We found that 23% of all patients exhibit a genetic signature consistent with a high ACC tumor response rate to Entinostat and Cisplatin. Our study provides compelling preclinical data supporting the deployment of a powerful systemic anticancer therapy crafted and explicitly tested for ACC tumors.

Published
2023

34. Abstract 1092: Correlation of platinum sensitivity with donor patient treatment status in a panel of breast, ovary, uterine, and lung XPDX models

Author

Simonson, Alyssa, primary, Flores, Johnnie, additional, Firova, Lizette, additional, Hernandez, Christian, additional, Harris, Morgan, additional, Papadopoulos, Kyriakos, additional, Rasco, Drew, additional, Patnaik, Amita, additional, White, Allan, additional, Smith, Lon, additional, Drengler, Ronald, additional, Lang, Amy, additional, Beeram, Murali, additional, and Wick, Michael J., additional

Published
2022
Full Text
View/download PDF

35. Abstract 412: Correlation of drug sensitivity to clinical response in XPDX models established from patients treated with KRAS-G12C-inhibitor therapy

Author

Flores, Johnnie, primary, Simonson, Alyssa, additional, Forofontov, Peter, additional, Stackpole, Anna, additional, Rasco, Drew, additional, Patnaik, Amita, additional, Papadopoulos, Kyriakos, additional, DesRochers, Teresa, additional, Williams, Natalie, additional, Drengler, Ronald, additional, Smith, Lon, additional, and Wick, Michael J., additional

Published
2022
Full Text
View/download PDF

38. Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer

Author

Furman, Craig, primary, Puyang, Xiaoling, additional, Zhang, Zhaojie, additional, Wu, Zhenhua J., additional, Banka, Deepti, additional, Aithal, Kiran B., additional, Albacker, Lee A., additional, Hao, Ming-Hong, additional, Irwin, Sean, additional, Kim, Amy, additional, Montesion, Meagan, additional, Moriarty, Alyssa D., additional, Murugesan, Karthikeyan, additional, Nguyen, Tuong-Vi, additional, Rimkunas, Victoria, additional, Sahmoud, Tarek, additional, Wick, Michael J., additional, Yao, Shihua, additional, Zhang, Xun, additional, Zeng, Hao, additional, Vaillancourt, Frédéric H., additional, Bolduc, David M., additional, Larsen, Nicholas, additional, Zheng, Guo Zhu, additional, Prajapati, Sudeep, additional, Zhu, Ping, additional, and Korpal, Manav, additional

Published
2022
Full Text
View/download PDF

39. Abstract P5-01-09: Establishment and characterization of two simultaneously developed T-DM1-resistant, ER+/HER2+ XPDX models from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)

Author

Flores, Johnnie R, primary, Stackpole, Anna, additional, Garza, Abimael, additional, Ulmer, Alexandra, additional, Simonson, Alyssa, additional, Papadopoulos, Kyriakos, additional, Cabang, April, additional, Ma, Jun, additional, Patnaik, Amita, additional, Rasco, Drew, additional, Lang, Amy, additional, Rodriguez, Gladys, additional, Beeram, Murali, additional, and Wick, Michael J, additional

Published
2022
Full Text
View/download PDF

40. Abstract P5-01-11: Nonclinical activity of fulvestrant in a panel of ER+ breast XPDX models representing clinically acquired and innate resistance to endocrine therapies

Author

Cabang, April, primary, Moreno, Crystal, additional, Flores, Johnnie R, additional, Boedeker, Jenna, additional, Simonson, Alyssa, additional, Ma, Jun, additional, Lang, Amy, additional, Rodriguez, Gladys, additional, Rosenthal, Arthur, additional, Papadopoulos, Kyriakos, additional, Patnaik, Amita, additional, Rasco, Drew, additional, Smith, Lon, additional, Beeram, Murali, additional, Drengler, Ronald, additional, Rodriguez, Luis, additional, Abbate, Steven, additional, Ulmer, Scott, additional, and Wick, Michael J, additional

Published
2022
Full Text
View/download PDF

41. Abstract P5-01-06: Establishment and characterization of luminal A breast XPDX models from patients with acquired resistance to CDK 4/6 inhibitors

Author

Hernandez, Tatiana, primary, Kneifel, Dustin, additional, Simonson, Alyssa, additional, Flores, Johnnie R, additional, Quick, Sarah, additional, Cabang, April, additional, Ulmer, Alexandra, additional, Papadopoulos, Kyriakos, additional, Lang, Amy, additional, Rodriguez, Gladys, additional, Beeram, Murali, additional, Rasco, Drew, additional, Patnaik, Amita, additional, Ulmer, Scott, additional, and Wick, Michael J, additional

Published
2022
Full Text
View/download PDF

42. Contributors

Author

Abernethy, Darrell R., primary, Atkinson, Arthur J., additional, Budris, William, additional, Chen, Ligong, additional, Collins, Jerry M., additional, Daniels, Charles E., additional, Dedrick, Robert L., additional, Flockhart, David A., additional, Foster, David M., additional, Fotis, Michael, additional, Frederiksen, Marilynn C., additional, Garzone, Pamela D., additional, Giacomini, Kathleen M., additional, Gombar, Charles T., additional, Grudzinskas, Charles, additional, Hargreaves, Richard J., additional, Holford, Nicholas H.G., additional, Huang, Shiew-Mei, additional, Jones, Bridgette L., additional, Kearns, Gregory L., additional, Klimas, Michael, additional, Lau, S.W. Johnny, additional, Lertora, Juan J.L., additional, Lesko, Lawrence J., additional, Lowe, Elizabeth S., additional, Markey, Sanford P., additional, Miller, Raymond, additional, Morrison, Paul F., additional, Mould, Diane R., additional, Parekh, Ameeta, additional, Peck, Carl C., additional, Penzak, Scott R., additional, Robertson, Sarah, additional, Rolan, Paul, additional, Rowland, Malcolm, additional, Ryder, Steven W., additional, Sahajwalla, Chandrahas G., additional, Sausville, Edward A., additional, Stika, Catherine S., additional, Susla, Gregory M., additional, Takimoto, Chris H., additional, Van Den Anker, John N., additional, Vicini, Paolo, additional, Ware, Joseph A., additional, Weiner, Ethan S., additional, Wick, Michael J., additional, Woodcock, Janet, additional, and Zhang, Lei, additional

Published
2012
Full Text
View/download PDF

46. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

Author

Sudhan, Dhivya R., primary, Guerrero-Zotano, Angel, additional, Won, Helen, additional, González Ericsson, Paula, additional, Servetto, Alberto, additional, Huerta-Rosario, Mariela, additional, Ye, Dan, additional, Lee, Kyung-min, additional, Formisano, Luigi, additional, Guo, Yan, additional, Liu, Qi, additional, Kinch, Lisa N., additional, Red Brewer, Monica, additional, Dugger, Teresa, additional, Koch, James, additional, Wick, Michael J., additional, Cutler, Richard E., additional, Lalani, Alshad S., additional, Bryce, Richard, additional, Auerbach, Alan, additional, Hanker, Ariella B., additional, and Arteaga, Carlos L., additional

Published
2020
Full Text
View/download PDF

47. Contributors

Author

Abernethy, Darrell R., primary, Atkinson, Arthur J., additional, Balis, Frank, additional, Berg, Mary J., additional, Bertilsson, Leif, additional, Bertino, Joseph S., additional, Calis, Karim Anton, additional, Chen, Maylee, additional, Collins, Jerry M., additional, Daniels, Charles E., additional, Decker, Shannon, additional, Dedrick, Robert L., additional, Frederiksen, Marilynn C., additional, Flockhart, David A., additional, Foster, David M., additional, Fox, Elizabeth, additional, Garzone, Pamela D., additional, Grudzinskas, Charles V., additional, Holford, Nicholas H.G., additional, Lesko, Lawrence J., additional, Markey, Sanford P., additional, Miller, Raymond, additional, Morrison, Paul F., additional, Mould, Diane R., additional, Nafziger, Anne N., additional, Peck, Carl C., additional, Penzak, Scott R., additional, Preusch, Peter C., additional, Reidenberg, Marcus M., additional, Robertson, Sarah M., additional, Rolan, Paul Edward, additional, Sahajwalla, Chandrahas G., additional, Sausville, Edward A., additional, Sidawy, Emil N., additional, Lowe, Elizabeth Soyars, additional, Stika, Catherine S., additional, Susla, Gregory M., additional, Takimoto, Chris H., additional, Wick, Michael J., additional, and Young, Lind R., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results